NanoSOD reduces adipose tissue inflammation in obesity (1107.10)

Abstract

Obesity‐linked hypertension is resistant to antihypertensive drugs and, adipose tissue (AT) inflammation is considered to mediate the pathological consequences of obesity. The objective of this study is to determine the effectiveness of nanoformulated copper/zinc superoxide dismutase (nanoSOD) in reducing AT inflammation in obesity. Wild type mice were fed a high fat (HF) diet (45% fat) for 8 or 13 wk followed by 2 wk treatment with native or nanoSOD. The drug uptake studies showed that nanoSOD was accumulated in the visceral AT to a greater extent than native SOD in obese mice. The mice fed a HF diet for 8 wk followed by 2 wk treatment with nanoSOD showed an increase in SOD content in stromal vascular cells (SVCs) collected from AT and in the plasma. These mice also showed a reduction in nitrotyrosine level, a marker of superoxide induced oxidative stress, in SVCs. The AT inflammatory markers showed a trend towards a decrease. The serum toxicity markers did not alter in nanoSOD compared to other groups suggesting that the nanoSOD is safe to use in vivo. After 13 wk on a HF diet followed by 2 wk treatment, the SVCs derived from AT of nanoSOD treated mice showed a decrease in the mRNA levels of MCP‐1 and MIP‐1α. Also, the MCP‐1 mRNA and protein levels in total AT was reduced to a greater extent in nanoSOD compared to native SOD treated mice. Our data suggest that nanoSOD may be a potential therapeutic agent to ameliorate obesity‐linked cardiovascular risk factors, in particular, systemic hypertention.Grant Funding Source: National Institutes of Health (NIH‐NIGMS)